Unique, patented technology

Prior to surgery, it is very difficult today to determine if rectal cancer has spread to the lymph nodes. The spread is not verified until the surgical preparate has been examined microscopally. 

The five-year survival rate for persons suffering from rectal cancer is currently no more than 67 percent. Our system aims to fill the void in the current care, and we have thus developed a novel medical imaging method based on magnetomotive ultrasound. 

Among other things, we want to enable more patients to get minimally invasive surgical procedure instead of extensive, unnecessary and risky surgery.

Our innovation comprises the combination of nanotechnology with modern ultrasound technology. We combine a magnetic field with diagnostic ultrasound in an entirely new way. As such, we can bring the inherently cost-efficient ultrasound technology into completely new application areas. Our primary focus is on rectal cancer and the mapping of cancer spread to nearby lymph nodes. The spread of cancer to nearby lymph nodes is an important marker for the cancer’s progression. It is also essential to be able to design a personalized treatment.

The stand-alone, portable system comprises a hand-held probe, an ultrasound scanner and a software that controls the system and generates the imaging signal, which we call NanoTrace®. 

Development is conducted together with reputable development companies, in well-defined stages with clear deliverables. This optimizes the possibility of efficiently developing a commercial product for the market. 

How does it work?

The technology utilizes iron-oxide-based nanoparticles as a contrast agent to clearly indicate lymph nodes close to the tumour and provide an indication of whether they contain metastases. By means of an alternating magnetic field, generated within the hand-held probe, the particles are set in motion. A vibration signal appears in the tissue where particles are present. The signal is detected with ultrasound and processed by the software, which filters, enhances and then visualizes the image-generating NanoTrace® signal.

Advantages of the technology

Better image resolution than MRI

Clear differentiation between diseased and healthy tissue

Portable and simpler than MRI

Can be used bedside in hospitals

Clinical trials

Clinical trial on surgically removed rectal cancer tissue, with the first generation of the company’s portable system, is conducted at Sahlgrenska University Hospital in Gothenburg. Ethical application for clinical trail is approved at Skånes University Hospital in Malmö.

The results of these clinical development studies will be used to evaluate the effectiveness of our existing system and guide the design of our next system for commercialization. Together, these two studies will provide us with a comprehensive analysis of the system’s performance, as both patients with different positions of the tumor in the rectum and patients with different stages of cancer are included. The studies will compare results from NanoEcho’s diagnostic method with other imaging modalities such as magnetic resonance imaging (MRI) and pathology. 

Sahlgrenska University Hospital and Östra Sjukhuset, Gothenburg

The clinical trial lead by Eva Angenete, chief physician and professor of rectal surgery at Sahlgrenska University Hospital, started in June 2021 . The study will include about 25 patients and last for one to two years from start date.

– Our study will ensure that the system works for straightforward diagnosis of lymphatic spread. This could be a very interesting and positive development towards a simpler and cheaper diagnostic tool, says chief physician and professor of surgery Eva Angenete.

Skånes University Hospital, Malmö

Ethical application is approved at Skånes University Hospital in Malmö. The clinical trial is planned to be led by Henrik Thorlacius, chief physician and professor of rectal surgery at Skånes University Hospital. The study will include about 40 patients and last for one to two years from start date.

– My hope with the clinical study is that we will be able to validate that NanoEcho’s instruments can identify lymph nodes with cancer cells in them with high precision, says chief physician and professor of surgery Henrik Thorlacius.

Photo: Sahlgrenska Universitetssjukhuset.
Photo: Emil Langvad

Nanoecho.se använder cookies för att förbättra hemsidans funktionalitet för dig som användare. Är det okej?